Our fibrinolytic potential.
Several methods of determining fibrinolytic activity were explored. The methods which gave the most satisfactory appraisal of the amount of fibrinolysin administered were as follows: euglobulin fraction on a prepared fibrin clot; euglobulin fraction method on benzoylarginine methyl ester; whole blood clot spontaneous lysis method. At present, the first of these three methods is the technique of choice. A preparation devised to observe the lysis of blood clots in vivo under the action of human fibrinolysin is described. In this preparation the successful lysis of fresh blood clots produced experimentally in segments of autogenous veins anastomosed to arteries was observed. The administration of plasmin by aerosol was followed by an increased lytic activity of the plasma of premature infants. Six patients in whom the clinical diagnosis of pulmonary hyaline membrane was made recovered completely after the treatment with human plasmin by aerosol. Forty-three percent of the children with the same diagnosis in whom plasmin was not used died (control subjects). Large doses of human fibrinolysin administered by the intravenous route prevented the formation of peritoneal adhesions in 100% of the animals treated. Adhesions developed in all of the dogs in which the intraperitoneal route was used. Fibrinolytic activity in the peripheral blood was increased considerably in all of the animals in which adhesions did not develop. No hemorrhagic phenomena other than slight oozing of the wounds were observed.
D000336:Aerosols; D000818:Animals; D004285:Dogs; D004341:Drug Evaluation; D005341:Fibrinolysin / Q000008:administration & dosage / Q000627:therapeutic use*; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D006819:Hyaline Membrane Disease / Q000188:drug therapy*; D007231:Infant, Newborn; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008722:Methods; D010532:Peritoneal Diseases / Q000188:drug therapy*; D011183:Postoperative Complications / Q000188:drug therapy*; D000267:Tissue Adhesions / Q000188:drug therapy
D000336:Aerosols; D005341:Fibrinolysin